{"id":"W2997875868","doi":"10.1111/bjd.18851","title":"A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":172,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada); Dalhousie University; Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Double blinded; Plaque psoriasis; Psoriasis; Randomized controlled trial; Dermatology; Head start; Internal medicine; Placebo; Secukinumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003417732,0.002286747,0.005622009,0.0005770898,0.000574339,0.001897831,0.001241423,0.002887568,0.00747696],"category_scores_gemma":[0.003057237,0.001236998,0.003217429,0.0005110267,0.001489191,0.001511481,0.0005414405,0.003403097,0.001497073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000808151,"about_ca_system_score_gemma":0.001410985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007399219,"about_ca_topic_score_gemma":0.001353127,"domain_scores_codex":[0.9981138,0.001045208,0.0001629289,0.0003315826,0.0001490803,0.000197468],"domain_scores_gemma":[0.9981651,0.0006522856,0.0004235585,0.0001992667,0.0001427704,0.0004169688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9908391,0.00263512,0.0001206101,0.0003132137,0.0005330252,0.000009884836,0.00001869135,0.00009232658,0.000864471,0.00002365891,0.0001628546,0.004387054],"study_design_scores_gemma":[0.9444423,0.05396764,0.0005578983,0.00002317786,0.0004282304,0.0000124484,0.000008762381,0.0001668798,0.0001742125,0.00006166261,0.0001467934,0.00001004292],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802642,0.009365853,0.001031724,0.0006571902,0.001158858,0.004571341,0.0008912851,0.0002049401,0.001854619],"genre_scores_gemma":[0.9844425,0.00370117,0.001597309,0.0008957934,0.0009591657,0.004607802,0.0006137873,0.00003897804,0.003143465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00747696,"threshold_uncertainty_score":0.02501291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01955120370552401,"score_gpt":0.2670848621733414,"score_spread":0.2475336584678174,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}